Courtney Thorne

Partner
Full contact info

I take life sciences companies public and then I'm there to help clients navigate the waters of being an SEC reporting company.

Passions

Dolly Parton, my Labradoodle

Fashion and interior design

Exploring neighborhood coffee shops 

Travel (next stop: Morocco)

Experience

Abivax Announces $235.8 Million IPO

October 20, 2023

Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.

Read more

Related contacts

Div Gupta
Partner, New York
Marc Recht
Partner, Boston
Ryan Sansom
Partner, Boston
Denny Won
Partner, San Francisco
Aaron Pomeroy
Partner, Colorado
Richard Segal
Partner, New York
Nyron J. Persaud
Partner, New York
Madhuri Roy
Partner, Palo Alto
Courtney Thorne
Partner, Boston
Elizabeth Anne Wright
Partner, Brussels
Xander Lee
Partner, Los Angeles Santa Monica
Phil Mitchell
Partner, New York
Stephanie Gentile
Partner, New York
Kevin King
Partner, Washington DC
Katie Kazem
Partner, Reston
Natasha Leskovsek
Of Counsel, Washington DC
Rebecca Ross
Special Counsel, Washington DC
Randy Sabett
Special Counsel, Washington DC
Jennifer Shanley
Special Counsel, New York
Reid Hooper
Special Counsel, Washington DC
Karen Tsai
Special Counsel, Washington DC
Minkyu Park
Associate, New York
Jesse Schulman
Associate, Washington DC
Barry Kuang
Associate, Boston
Olivia Creser
Associate, New York
Peter A. Haddad
Associate, San Diego
Samuel Paullin
Associate, Chicago
Evan Leitner
Associate, New York
Rick Jantz
Associate, Los Angeles Santa Monica
Cara Buchicchio
Associate, New York
Jason Valentine
Associate, Washington DC
Jessica Koffel
Associate, Brussels
Mor Agam
Associate, New York
Cathy Rude
Senior Paralegal, Boston

Related Practices & Industries

Merus – $172.5 Million Follow-on Offering

August 14, 2023

Cooley advised the underwriters in Merus’ $172.5 million follow-on offering. Jefferies, BofA Securities, Guggenheim Securities and William Blair acted as joint book-running managers for the offering. Merus is a clinical-stage oncology company developing innovative, full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics. Partners Denny Won, Courtney Thorne and Div Gupta led the Cooley team.

Related contacts

Denny Won
Partner, San Francisco
Courtney Thorne
Partner, Boston
Div Gupta
Partner, New York
Evan Leitner
Associate, New York
David D. Kim
Associate, San Francisco
Charles York
Associate, New York
Kindall G. Jackson
Associate, Washington DC
Peter A. Haddad
Associate, San Diego

Related Practices & Industries

CinCor Pharma – $212 Million IPO

January 7, 2022

Cooley advised CinCor Pharma on its upsized $212 million initial public offering of 13,290,813 shares of common stock, which included a partial exercise of the underwriter’s option to purchase additional shares of common stock. CinCor, whose shares now trade on the Nasdaq Global Market under the symbol CINC, is a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CinCor’s IPO was one of the first IPOs of 2022. Partners Ryan Sansom, Div Gupta and Courtney Thorne led the Cooley team.

Related contacts

Ryan Sansom
Partner, Boston
Div Gupta
Partner, New York
Courtney Thorne
Partner, Boston
Barry Kuang
Associate, Boston
Alexander Fullman
Associate, New York
Cathy Rude
Senior Paralegal, Boston
Danielle Gershowitz
Associate, New York

Related Practices & Industries

Exscientia – $510.4 Million IPO

October 6, 2021

Cooley advised Exscientia, an AI-driven pharmatech company based in Oxford, United Kingdom, on its $510.4 million initial public offering, including concurrent private placements to SoftBank and the Bill & Melinda Gates Foundation. Partners David Boles, Claire Keast-Butler, Div Gupta and Marc Recht led the Cooley team advising Exscientia.

Read more

Related contacts

David Boles
Partner, London
Claire Keast-Butler
Partner, London
Div Gupta
Partner, New York
Marc Recht
Partner, Boston
David Wilson
Partner, London
Chris Stack
Partner, London
Dayne Brown
Associate, New York
Margaret D. Suh
Associate, New York
Meg Begur
Associate, London
Nicola Squire
Partner, London
Jack Jones
Associate, London
Charlotte Irvine
Associate, London
Tom Goodman
Partner, London
Paula Holland
Partner, London
Aaron Pomeroy
Partner, Colorado
Calvin Lee
Associate, New York
Ivor Elrifi
Partner, New York
Courtney Thorne
Partner, Boston

Related Practices & Industries

Finch Therapeutics – $128 Million IPO

April 8, 2021

Cooley advised Finch Therapeutics on its $127.5 million initial public offering of 7,500,000 shares of common stock. Finch Therapeutics, whose securities now trade on the Nasdaq Global Select Market under the symbol FNCH, is a clinical-stage microbiome therapeutics company. Partners Div Gupta and Ryan Sansom led the Cooley team.

Related contacts

Div Gupta
Partner, New York
Ryan Sansom
Partner, Boston
Courtney Thorne
Partner, Boston
Trey Reilly
Associate, New York
Michael Bruno
Associate, New York
Pengli Li
Associate, Boston

Related Practices & Industries

View more

Rankings & accolades

Massachusetts Super Lawyers: Rising Star in Business/Corporate Law and Securities & Corporate Finance
(2015 – 2023)

#1 Firm for European FPI US IPOs since 2016

Memberships & affiliations

Boston Bar Association

Healthcare Businesswomen's Association

PubCo @ Cooley Blog

Focus on providing dynamic thought leadership and curated content for the public securities arena